Cardiovascular diseases (CVD), such as myocardial infarction (MI), constitute one of the
world's leading causes of annual deaths. This cardiomyopathy generates a tissue scar with …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Background The value of guided therapy (GT) with anti-P2Y12 drugs in percutaneous
coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized …

Objective: Previous studies on the efficacy and safety of genotype-guided antiplatelet
therapy in patients with coronary artery disease (CAD) or undergoing percutaneous …

Background Conflicting results were reported by randomized controlled trials (RCTs)
exploring guided therapy (GT) with anti-P2Y12 drugs in patients undergoing percutaneous …

Dual antiplatelet therapy (DAPT) is the standard approach to prevent thrombotic events in
patients undergoing percutaneous coronary intervention and presenting with chronic or …

Introduction Clopidogrel is the only antiplatelet agent whose activity is significantly affected
by CYP2C19 polymorphism. Areas covered This review has summarized the available …

Oral P2Y12 inhibitors represent the cornerstone of treatment for patients undergoing
percutaneous coronary interventions (PCI)[1]. In patients undergoing PCI, oral P2Y12 …

Dual antiplatelet therapy, consisting of aspirin and a P2Y12 inhibitor, represents the
standard of care for patients undergoing percutaneous coronary intervention (PCI) or those …

Background The prevalence and the role of CYP2C19 gene mutations concerning recurrent
Cardiovascular Events (CVEs) among patients treated with clopidogrel is still controversial …